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Summary A series of 301 cases of male breast carcinoma has been analysed; of these, 292 have been treated
at The Christie Hospital, Manchester and followed-up for a maximum of 15 years. The mean age was 63
years. The corrected survival was 52%, 38% and 36% at 5, 10 and 15 years respectively. For clinical Stage I,
the 15 year survival was 61%.
Since 1976, adjuvant Tamoxifen for one year has been administered to patients with operable Stage II
(path) and Stage III disease following surgery and radiotherapy. Twenty-three patients so treated have a
corrected survival of 55% at 5 years compared to 28% previously. Of 22 tumours assayed for oestrogen and
progesterone receptors, 86% showed a positive result.
For recurrent/metastatic disease, the drug Tamoxifen is recommended as the treatment of choice.
Male breast carcinoma remains a very rare disease,
with approximately one male being affected for
every 100 cases of human breast carcinoma. The
average annual death rate for male breast car-
cinoma from 1968-1978 in England and Wales
(Gardner et al., 1983) was 874 men or 3 per million
compared to 123,636 women with breast carcinoma
or 448 per million.
Very few series have been reported from single
Institutions (Holleb et al., 1968; Scheike, 19.75;
Langlands et al., 1976) and the paucity of cases has
led to several series being pooled in reviews of the
world literature (Meyskens et al., 1976; Everson &
Lippman 1979).
The Author has previously reported on 200 cases
of male breast carcinoma; (Ribeiro, 1977) an ad-
ditional 101 patients have since been registered at
The Christie Hospital & Holt Radium Institute
giving a total of 301 cases. It was felt that an
analysis of this series would reflect the changes that
have taken place in the management of this disease.
Patients
The clinical records of all the patients have been
carefully studied and, for the sake of uniformity,
the clinical staging used throughout has been that
of the UICC International Staging of 1968.
Histological confirmation was available in all the
patients except a very few with Stage IV disease.
Survival curves show the acturial survival rates.
These have been calculated firstly to include all
deaths whatever the cause and, secondly, counting
deaths from breast carcinoma only. A patient who
dies from intercurrent disease at time T after treat-
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ment, is included as being at risk up to the time T
and then omitted from the group at all times
greater than T. Significant differences between
curves were calculated by the use of the log Rank
test (Peto & Peto, 1972).
Since 1974, the following investigations are car-
ried out whenever possible on all patients registered
at The Christie Hospital: Full blood count, bio-
chemical profile, X-rays of the chest, lumbar spine
and pelvis and a whole body Technetium 99 bone
scan.
More specialised investigations have included es-
timation of serum oestradiol-17beta, testosterone,
luteinizing hormone (LH) and follicle stimulating
hormone (FSH) concentrations by standard radio-
immunoassay methods. Where tumour tissue was
available Oestrogen (REC) and Progesterone (RPC)
receptors have been measured by the dextran
charcoal method previously described (Barnes et al.,
1977).
Survival curves show acturial survival rates and
have been calculated in two ways; first, including
all deaths whatever the cause and secondly counting
deaths from breast carcinoma only. A patient who
dies of intercurrent disease at time T after treat-
ment is included as being at risk up to time T and
then omitted from the group at risk at all times
greater than T. Significant differences between
curves were worked out by using the log Rank test
(Peto & Peto, 1972).
Results
Symptoms and signs
The great majority of patients (81%) presented with
a palpable lump usually associated with an increase
in size; pain was a feature in only 4% of these
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lumps. Breast ulceration occurred in 6%, and 10%
had lesions related to the nipple such as ulceration,
discharge or retraction. In 3% MBC was an inci-
dental finding or the patient presented with wide-
spread metastatic disease.
No patient in this series presented with bilateral
primary MBC. Between 1941 and 1961 the duration
of symptoms was recorded as being a minimum of
one month and a maximum of 300 months with a
mean of 18.5 months. Between 1962 and 1983 the
mean duration of symptoms has reduced to 11
months.
Results ofinvestigations
Table I summarises the findings with regard to the
endocrine profile. Forty one patients with male
breast carcinoma have had an estimation of LH
and FSH, 31 patients, plasma testosterone and 28
patients plasma oestradiol. The results have been
compared with the findings in 31 normal males as
controls. The age of the controls ranged from 37
years to 89 years to match the age range of the
male breast carcinoma patients. The younger men
were members of the hospital staff and the older
men were volunteers from attendants at a geriatric
Day Centre. None of the controls were on any
form of hormone medication and none were on
treatment for any disease. The range of values is
shown together with the mean and standard error.
Because of the skewed distributions in values be-
tween the male breast carcinoma patients and con-
trols, the non-parametric Mann-Whitney U test
(Siegel, 1966) has been used. The differences were
regarded as significant when P<0.02. The mean
values of breast carcinoma males showed no statisti-
cally significant differences from controls for
oestradiol-17 beta (z=1.59 P=0.11), LH (z=1.81
P=0.07), FSH (z= 1.87 P=0.06) testosterone
(z= 1.59 P=0.11).
Oestrogen (REC) and Progesterone (RPC) re-
ceptors have been measured in 22 patients with
male breast carcinoma primary tumours and 6
secondary skin deposits. The dextran charcoal
method previously described by Barnes et al. (1977)
was used. A specimen was regarded as having
positive cytoplasmic activity if it contained a mini-
mum of 5fmolmg-1 cytosol protein for REC and
15fmolmg-1 cytosol protein for RPC. The protein
concentration had to be at least 0.7mgl-1. Thirteen
of the 16 primary tumours (81%) showed positive
receptor activity; 9/16 primary tumours were
positive for both REC and RPC, 3 were positive
for REC only and one positive for RPC only. Of
the 6 secondary tumours 3 were positive for REC
and 3 for RPC. There was no correlation between
REC and RPC concentration and the age of the
patient. A survey of the world literature (Everson &
Lippman, 1979) showed that REC was present in
84% of tumour samples from MBC patients and
RPC in 73%; a significant negative correlation was
found between REC concentration and age, which
was absent in the present series.
Results of treatment
From 1941 to 1983 inclusive, 301 patients have
been registered with a diagnosis of male breast
carcinoma; of these 292 have been treated. Of the
301 patients 9 were not treated as it was felt they
only had a short time to live because of very
widespread disease. The remaining 292 patients
were treated and form the basis of the analysis.
The age at presentation has altered little over the
years, with the majority of patients presenting in
their fifth and sixth decades. The youngest patient
was aged 21 years and the oldest 91 years with a
mean of 63 years.
Clinically, 38% presented with Stage I disease,
21% with Stage II, 26% with Stage III and 15%
with Stage IV.
Surgery
Prior to 1961, the standard treatment for operable
male breast carcinoma was a radical mastectomy
with or without post-operative radiotherapy. Since
1961 a simple mastectomy with post-operative
radiotherapy is now the most common treatment,
with a few old and frail patients having a wide
Table I Hormone profile of male breast carcinoma patients and controls
Oestradiol Testosterone LH FSH
(pmoll-1) (nmoll-1) (IUl ') (IUl-1)
Patients
Mean (s.e.) 124.0 (26.4) 20.1 (1.38) 7.9(1.21) 7.4(1.22)
Range 0-740 3.0-34.0 2.0-50.0 1.0-37.0
Controls
Mean (s.e.) 66.7(7.11) 16.8 (1.33) 5.4(0.50) 4.4(0.73)
Range 15-217 5.5-29.0 2.0-15.0 1.0-18.0MALE BREAST CARCINOMA 117
excision with radiotherapy. Table II illustrates this
trend.
The majority of patients with Stage III disease
have been treated primarily by radiotherapy fol-
lowed by endocrine or chemotherapy, (where possi-
ble, based on receptor data) when they developed
recurrent or metastatic disease. More recently, the
author has used adjuvant endocrine therapy for
Stages II (path) and III (see below).
There were 40 patients aged <50 years, 52 aged
50-59, 109 aged 60-69 and 90 aged >70 years.
There is no significant difference in the corrected
survival of these age groups (P= 0.14).
The effect of delay in presentation on survival is
shown in Figure 2. Although the patients presenting
within the 6-11 month period appear to have a
poor survival, overall the trend is significantly in
favour of those patients presenting earlier (X2 for
trend=5.21 ondfP=0.02)
Table II Surgical trends by decades
Period RM SM+RT Excision
1941-1951 24 5 2
1952-1961 35 12 6
1962-1971 17 23 9
1971-1983 15 53 8
Total 91 93 25
RM=Radical Mastectomy.
SM =Simple Mastectomy.
RT= Radiotherapy.
Survival
The overall survival of the whole group of 292
patients was 44%, 23% and 14% at 5, 10 and 15
years respectively. When corrected for intercurrent
deaths, the equivalent figures are 52%, 38% and
36%. The high rate of death from causes other
than male breast carcinoma has been previously
noted (Scheike, 1975; Moss, 1964; Norris & Taylor,
1969) and, for the latter reason, the following
survival curves have all been corrected (cf. Methods
and Statistics).
Figure 1 shows the influence of clinical staging
on corrected survival. There was a statistically
significant worsening of prognosis from clinical
Stage I-IV (P= <0.0001).
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symptoms.
Corrected survival by duration of
Adjuvant Tamoxifen
In a previous report (Ribeiro, 1977) it was shown
that male breast carcinoma patients with Stage I
disease had a corrected survival comparable with
that of female breast carcinoma patients matched
for age, stage and type of treatment. However male
patients with Stage II and Stage III disease did
significantly worse than equivalent female patients
(Figure 3).
Since 1976, all male breast carcinoma patients
with Stage II disease (axillary node involvement)
and Stage III disease confined to the breast (T3a)
have been put on adjuvant Tamoxifen (Nolvadex)
for 12 months following definitive surgery and
radiotherapy. The dosage of Tamoxifen was 20mg
daily. None of the patients stopped the drug
because of side effects. Twenty-three patients have
been treated in this way. Twelve patients were
Stage II (path) and I1 patients were Stage III. The
hormone receptor status was known in 8 patients, 7
of whom had tumours which were positive for both
oestrogen and progesterone receptors and, one
patient whose tumour was negative for hormone
receptors.
The minimum follow-up has been 3 months and
the maximum 78 months. Again from Figure 3 it
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Figure 3 Corrected survival of male vs female
patients+adjuvant Tamoxifen (male).
can be seen that the corrected survival of these 23
patients now approximates that of the female
patients with a 5 year survival of 55% compared to
28% previously. The numbers of patients treated
with adjuvant Tamoxifen is as yet very small.
Furthermore there are dangers in suggesting im-
proved survival benefit with the use of historical
controls, but with a disease as rare as male breast
carcinoma, it would be impossible to get enough
patients to run a controlled clinical trial even on
ain international basis.
Double primary tumours
In the present series, 5% of patients were treated
for other primary malignant tumours; these were all
subsequent to treatment for male breast carcinoma.
Histological material was available in all cases so
there was no question of these tumours being
metastatic disease. Other authors have noted this
phenomenon and reported an incidence varying
from 7.5% to 12.5% in their series (Holleb et al.,
1968, Scheike 1975; Langlands et al., 1976). In all
the series there has been a preponderance of car-
cinoma of the large intestine (45%). Other second
primary tumours in the present series include car-
cinomas of the stomach, bladder, pancreas, skin,
testis and lung. One patient had male breast car-
cinoma followed by chronic lymphatic leukaemia,
carcinoma of the large bowel and, basal cell car-
cinoma of the skin all of which were successfully
treated,, the patient dying at the age of 85 years.
Recurrence/metastases
The majority of patients who develop recurrent
disease in the operative flaps and/or lymph node
drainage areas do so within 3 years of surgery.
There is no significant difference in local recurrence
between those patients having a radical mastectomy
and those having had a simple mastectomy and
post-operative radiotherapy.
In general, most of the patients with recurrent
and/or metastatic disease have been treated by
means of additive endocrine therapy rather than
orchidectomy. In a previous report (Ribeiro, 1976)
the author has shown that Diethylstilboestrol
caused objective regression of disease in 38% of 55
patients treated. Since then the drug Tamoxifen
Citrate (Nolvadex) has become widely available and
shown to be very effective in female breast car-
cinoma. In a recent paper (Ribeiro, 1983) the
author treated 24 patients with Tamoxifen for
advanced male breast carcinoma; 37.5% showed
objective regression (5 complete and 4 partial) of
disease for periods ranging from 8 months to 60
months; two patients had stabilisation of their
disease for 24 months each. Unlike stilboestrol,
healing responses were seen in bone as well as soft-
tissue and lung metastases. Another significant ad-
vantage of Tamoxifen is the almost total lack of
any side-effects.
Chemotherapy
As the response to endocrine therapy is so good
and also allowing for the fact that most of the
patients are elderly, cytotoxic therapy has been
reserved as second line treatment for those not
responding to endocrine therapy. Ten patients with
soft-tissue disease (breast, chest wall, lymph nodes)
have been treated with oral cyclophosphamide in a
dose of 50mg three times daily continously. Five of
the 10 patients had complete regression of their
disease for periods ranging from 8 months to a
maximum of 16 months. Five patients with soft-
tissue disease had 5-Fluoruracil one gram i.v. on
Day 1 and cyclophosphamide 200mg daily on days
2-4. Two of the 5 patients showed complete re-
gression for 4 and 5 months and the remainder
progressed. Three patients with lung and bone
metastases were treated with the standard CMF
Regimen followed by Adriamycin 30mgm .2 Only
one of the three patients had a partial response for
4 months.MALE BREAST CARCINOMA 119
Discussion
The primary treatment of operable male breast
carcinoma now mirrors the changes taking place in
the management of female breast carcinoma, with
simple mastectomy and radiotherapy replacing rad-
ical mastectomy. There would appear to be no
detrimental effect on local recurrence or overall
survival caused by this change.
In a previous report (Ribeiro, 1977) it was shown
that twice the number of Stage I patients presented
between 1957-1971 compared with 1942-1956. This
trend has continued and the mean duration of
symptoms has also been reduced. There is an
obvious advantage in presenting at an earlier stage
as the survival of Stage I disease is 61% at 15
years, which is relatively good considering the mean
age of the patients is 63 years.
Primary male breast carcinoma has high levels of
hormone receptor activity in at least 80% of cases.
Advantage can be taken of the latter fact in improv-
ing the survival of Stage II and III patients with
the use of adjuvant Tamoxifen therapy, as shown in
this series. Furthermore, the patients with recur-
rent/metastatic disease showed objective regression
in 37.5% of cases when treated with Tamoxifen.
Responses were noted in soft-tissue, lung and bone
metastases. Tamoxifen would thus re recommend
itself as the treatment of choice in this situation.
Hypothetically, there is no reason why these
patients should not respond to drugs which cause a
"medical adrenalectomy". The advantage of such a
response would be the abandonment of ablative
surgery as it has been in female breast carcinoma.
In this series, it has not been able to confirm any
abnormal endogenous hormone metabolism in male
breast carcinoma patients when compared with
matched controls. This is in agreement with Scheike
et al (1973) but not with other reports (Dao et al.,
1973, Calabresi et al., 1976; Nirmul et al., 1982).
The reasons for the difference may be in the
methodology, the paucity of patients, the choice of
controls, or even due to ethnic variations.
Finally, the management of male breast car-
cinoma should, as in the female counterpart, re-
main a continuously evolving process.
My thanks are due to my colleagues who referred their
cases. Also to Mr. R. Swindell for help with the statistics,
the Medical Illustration Department and Mrs M.A. Green
for typing the manuscript.
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